Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 0.72 |
| ▸ | PTGDR | Q13258 | 19/20 | 0.72 |
| ▸ | PDE2A | O00408 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781310 | 1.00 | TBXA2R (0.72) | TBXA2RPTGDRPDE2A | |
| SCHEMBL31018198 | 1.00 | TBXA2R (0.72) | TBXA2RPTGDRPDE2A | |
| SCHEMBL17589695 | 1.00 | TBXA2R (0.72) | TBXA2RPTGDRPDE2A | |
| SCHEMBL31156664 | 1.00 | TBXA2R (0.72) | TBXA2RPTGDRPDE2A | |
| SCHEMBL347601 | 1.00 | TBXA2R (0.72) | TBXA2RPTGDRPDE2A | |
| SCHEMBL347602 | 1.00 | TBXA2R (0.72) | TBXA2RPTGDRPDE2A | |
| SCHEMBL14572800 | 0.91 | TBXA2R (0.70) | TBXA2RPTGDRPDE2A | |
| SCHEMBL6270536 | 0.90 | TBXA2R (0.59) | TBXA2RPTGDRPDE2A | |
| SCHEMBL7788965 | 0.90 | TBXA2R (0.59) | TBXA2RPTGDRPDE2A | |
| SCHEMBL6268649 | 0.90 | TBXA2R (0.59) | TBXA2RPTGDRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9320723-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2016-04-26 | — | — | US | claimed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | claimed |
| US-20010047027-A1 | Prostaglandin D2 receptor antagonists | LABELLE MARC (US) | 2001-11-29 | — | — | US | claimed |
| US-12589089-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20250017900-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | UNIVERSITÉ PARIS CITÉ (FR) | 2025-01-16 | — | — | US | disclosed |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3256121-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-12-20 | — | — | EP | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075749-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007035478-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| EP-1274457-B1 | METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS USING PGD2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2005-11-30 | — | — | EP | disclosed |
| US-20030055077-A1 | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists | JONES THOMAS R (CA) | 2003-03-20 | — | — | US | disclosed |
| US-20010051624-A1 | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists | JONES THOMAS R (CA) | 2001-12-13 | — | — | US | disclosed |
| US-20010047027-A1 | Prostaglandin D2 receptor antagonists | LABELLE MARC (US) | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017900-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR, PTGDR2, PTGIR | TBXA2R 16/4885PTGDR 1/4885PDE2A 223/4885 |
| US-20010047027-A1 | Prostaglandin D2 receptor antagonists | PTGDR2, PTGDR, LTB4R2 | TBXA2R 21/4885PTGDR 2/4885PDE2A 1557/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885PDE2A 558/4885 |
| US-12589089-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | PTGIR, PTGDR, SSB | TBXA2R 13/4885PTGDR 2/4885PDE2A 346/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | TBXA2R 434/4885PTGDR 509/4885PDE2A 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.